Upstream Bio 3Q 2026: Revenue $395K, EPS ($0.75) — 10-Q Summary
Upstream Bio reported 3Q 2026 revenue of $395K, down 42.2% YoY, and a net loss of $41.19M, up 22.1% YoY. R&D expenses rose due to Phase 3 planning for CRSwNP and increased personnel costs. The company plans Phase 3 trials for severe asthma and CRSwNP in Q1 2027, with data from COPD and severe asthma trials expected in 2H 2027.
How this was made
The 30-second read
Why it matters
The results signal heightened cash burn and execution risk, likely prompting short‑term sell pressure.
Market read
The filing provides fresh financial data for a micro‑cap biotech, offering traders a concrete basis for short‑term positioning.
What to watch
Potential pipeline milestones in 2027 and any upcoming partnership announcements could offset short‑term weakness.
Background
Upstream Bio filed its Q3 2026 10‑Q, reporting a sharp drop in collaboration revenue and a widening net loss.
Ticker impact
10-Q shows Q3 revenue down 42% to $395K and net loss widening to $41.19M, indicating deteriorating financials.
likely pressure as the market prices in the weaker revenue and expanded loss
The disclosed numbers are fresh from the SEC filing and materially worse than prior quarter, a primary disclosure for a micro‑cap.
Market effects
Downbeat biotech earnings may weigh on the broader small‑cap biotech sector.
Limited to U.S. markets where the stock trades.
Minimal; impact confined to niche investors in biotech.
Counterpoint
If the Phase 3 programs succeed, the current loss could be viewed as a temporary cash burn for long‑term upside.
Key entities
- companyUpstream Bio, Inc.
Biotech firm developing therapies for severe asthma, CRSwNP, and COPD.
